CD35 Antibody (H-2): sc-166329

CD35 Antibody (H-2) is a mouse monoclonal IgG2b antibody that detects CD35 in human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD35, also known as complement receptor 1 (CR1), plays a crucial role in the immune response by serving as a receptor for complement components C3b and C4b, facilitating the phagocytosis of opsonized particles by neutrophils and monocytes. This function is vital for the clearance of pathogens and immune complexes, thereby maintaining homeostasis and preventing excessive inflammation. CD35 is predominantly expressed on granulocytes, monocytes, B cells, some natural killer cells, and erythrocytes, highlighting CD35′s importance in various immune processes. Notably, alterations in CD35 expression and function have been implicated in systemic lupus erythematosus (SLE), a chronic autoimmune disease characterized by the production of a wide array of autoantibodies and immune complex accumulation. In SLE patients, there is an observed increase in the proteolytic cleavage of leukocyte surface CD35, which may contribute to the dysregulation of immune responses. Sequence analysis indicates that Crry may serve as the mouse genetic homolog of human CD35 antigen encoded by the CR1 gene, further underscoring CD35′s relevance in both human and murine models of immune function. anti-CD35 antibody (H-2) is an essential tool for researchers investigating the complexities of immune regulation and the pathogenesis of autoimmune diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD35 Antibody (H-2) References:

1. Binding of immune complexes to erythrocyte CR1 (CD35): difference in requirement of classical pathway components and indication of alternative pathway-mediated binding in C2-deficiency.  |  Klint, C., et al. 2000. Scand J Immunol. 52: 103-8. PMID: 10886790
2. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies.  |  Hara, T., et al. 1992. Br J Haematol. 82: 368-73. PMID: 1384649
3. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.  |  Leslie, RG., et al. 2003. Eur J Immunol. 33: 3311-21. PMID: 14635039
4. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes.  |  Wagner, C., et al. 2006. Mol Immunol. 43: 643-51. PMID: 16360013
5. An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes.  |  Voynova, E., et al. 2008. Immunol Lett. 116: 168-73. PMID: 18262286
6. Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia.  |  Barros, MM., et al. 2009. Transfusion. 49: 154-60. PMID: 18954403
7. Overexpression of complement receptor type I (CR1, CD35) on erythrocytes in patients with hemoplasma infection.  |  Congbin, Y., et al. 2010. Microbiol Immunol. 54: 460-5. PMID: 20646210
8. Nonsteroidal antiinflammatory agents inhibit upregulation of CD11b, CD11c, and CD35 in neutrophils stimulated by formyl-methionine-leucine-phenylalanine.  |  Crowell, RE. and Van Epps, DE. 1990. Inflammation. 14: 163-71. PMID: 2138999
9. Complement Receptor Type 1 (CR1, CD35), the Inhibitor of BCR-Mediated Human B Cell Activation, Differentially Regulates TLR7, and TLR9 Induced Responses.  |  Mácsik-Valent, B., et al. 2019. Front Immunol. 10: 1493. PMID: 31312202
10. Increased expression of complement receptor type 1 (CR1, CD35) on human peripheral blood T lymphocytes after polyclonal activation in vitro.  |  Rodgaard, A., et al. 1995. Immunol Res. 14: 69-76. PMID: 7561342

The preferred CD35 antibody is CD35 Antibody (To5): sc-20055.